LACRISEK Spray
Dispositivo medico CE.
Spray a base di liposomi di vitamine A ed E, indicato per il trattamento della sindromedell'occhio secco.
Lacrisek stabilizza lo strato lipidico del film lacrimale, migliora e regola lalubrificazione della superficie oculare.

Modalità d'uso
Mantenendo gli occhi chiusi, applicare 1 o 2 spruzzi ad una distanza di circa 10 cm.Applicare 3 o 4 volte al giorno. Può essere utilizzato anche in presenza diprodotti cosmetici: in tal caso, applicare lo spray da una distanza maggiore (circa 20cm).

Componenti
Retinil palmitato (vitamina A); tocoferolo (vitamina E); fosfolipidi idrogenati;N-idrossimetil glicinato; EDTA disodico; fosfato di sodio monobasico; sodio fosfatobibasico; sodio cloruro; acqua purificata.

Formato
Flacone da 5 ml.

Bibliografia
  -   Bron AJ, Tiffany JM. The meibomian glands and tear film lipids.In: Sullivan D et al (Hrsg). Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. NewYork: Plenum Press, 1998: 281 -295
  -   Chew CKS, Jansweijer. Tiffany JM et al. An instrument forquantifying meibomian lipid on the lid margin: the Meibometer. Curr Eye Res 1993; 12:247-254
  -   Dinslage S, Stoffel W. Diestelhorst M et al. Tolerability andsafety of two new preservative-free tear film substitutes. Cornea 2002; 21: 352-355
  -   Heiligenhaus A, Koch JM, Kemper D et al. Therapie vonBenetzungsstörungen. Klin Monatsbl Augenheilkd 1994; 204: 162-168
  -   Heiligenhaus A, Koch JM. Kruse FE et al. Diagnostik undDifferenzierung von Benetzungsstörungen. Ophthalmologe 1995; 92: 6-11
  -   Glasgow BJ, Abduragimov AR, Farahbakhsh Z et al. Tear lipocalinbind a broad array of lipid ligands. Curr Eye Res 1995; 14: 363-372
  -   Glasgow BJ, Marshall G, Gasymov OK et al. Tear lipocalin:Potential lipid scavengers of the cornea1 surface. Invest Ophthalmol Vis Sci 1999; 40:3100-3107
  -   Goto E, Endo K, Suzuki A et al. Tear Evaporation Dynamics inNormal Subjects and Subjects with Obstructive Meibomian Gland Dysfunction. InvestOphthalmol Vis Sci 2003; 44: 533-539
  -   Goto E, Shimazaki J, Monden Y et al. Low-concentrationhomogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction.Ophthalmology 2002; 109: 2030- 2035
  -   Greiner JV, Glonek T, Korb DR et al. Meibomian glandphospholipids. Curr Eye Res 1996; 15: 371-375
  -   GreinerJV, Glonek T, Korb DR et al. Phospholipids in meibomiangland secretions. Ophthalmic Res 1996; 28: 44-49
  -   Kidd PM. Dietary phospholipids as anti-aging nutraceuticals.In: Klatz RA, Goldman R (Hrsg). Anti-Aging Medical Therapeutics. Chicago, IL: HealthQuest Publications; 2000: 283-301
  -   Korb DR, Greiner JV, Glonek T. The effects of anionic andzwitterionic phospholipids on the tear film lipid layer. In: Sullivan D et al (Hrsg).Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. Kluwer Academic/Plenum Publishers,2002: 495-499
  -   Lieber CS, Leo MA. Polyenylphosphatidylcholine decreasesalcohol-induced oxidative stress in the baboon. Alcoholism Clin Exp Res 1997; 21:375-379
  -   Lozato PA, Pisella PJ, Baudouin C. The lipid layer of thelacrimal tear film: physiology and pathology. J Fr Ophtalmol2001; 24 (6): 643-658
  -   Mathers WD, Daley TE. Tear flow and evaporation in patientswith and without dry eye. Ophthalmology 1996; 103: 664-669
  -   McCulley JP, Shine W. A compositional based model for the tearfilm lipid layer. Trans Am Ophthalmol Soc 1997; 95: 79-88; discussion 88-93
  -   McKeen D, Roth H, Doane M. Ocular drug delivery by the lid(lower lid delivery). Invest Ophthalmol Vis Sci 1996; 37: 77
  -   Miano F, Mazzone M, Giannetto A et al. Interface properties ofsimplified tear-like fluids in relation to lipid and aqueous layers composition. Adv ExpMed Biol 2002; 506 (Pt A): 405-417
  -   Nagyova B, Tiffany JM. Components responsible for the surfacetension of human tears. Curr Eye Res 1999; 19: 4-11
  -   Norn MS. Natural fat in external eye. Vital-stained by SudanIII powder. Acta Ophthalmol (Copenh) 1980; 58: 331-336
  -   Peters K, MillarTJ. The role of different phospholipids on tearbreak-up time using a model eye. Curr Eye Res 2002; 25
  -   Rolando M, Refojo MF, Kenyon KR. Increased tear evaporation ineyes with keratoconjunctivitis sicca. Arch Ophthalmol 1983; 101 : 557-558
  -   Roth HW, Koulen-Reitz G, Brunk G. Zur Langzeittherapie desTrockenen Auges mit einem Liposomenspray. Augenspiegel 2002; 48 (9): 54-58
  -   Schäfer W. Wywiol V. Lecithin der unvergleichlicheWirkstoff. Frankfurt/Main: Verlag Alfred Strothe, 1986
  -   Shimazaki J, Goto E, Ono M et al. Meibomian gland dysfunctionin patients with Sjogren syndrome. Ophthalmology 1998; 105 (8): 1485-1488
  -   Shimazaki J, Sakata M.Tsubota K. Ocular surface changes anddiscomfort in patients with meibomian gland dysfunction. Arch Ophthalmol 1995; 113:1266-1270
  -   Shine WE, McCulley JP. Keratoconjunctivitis sicca associatedwith meibomian secretion polar lipid abnormality. Arch Ophthalmol 1998; 116: 849-852
  -   Shine WE, McCulley JP. Polar lipids in human meibomian glandsecretions. Curr Eye Res 2003; 26: 89-94
  -   Shine WE, McCulley JP. Surface characteristics of a model tearfilm polar lipid layer. Invest Ophthalmol Vis Sci (ARVO) 2000; 41: 341
  -   Strempel I, Roth HW. Zur Therapie des Trockenen Auges mit einemSpray. Augenspiegel 1999; 45 (11 ): 16-21
  -   Sullivan BD, Evans JE, Cermak JM et al. Complete androgeninsensitivity syndrome: effect on human meibomian gland secretions. Arch Ophthalmol 2002;120 (12): 1689-1699
  -   Sullivan DA, Sullivan BD, Evans JE et al. Androgen deficiency,Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002; 966:211-222
  -   Tsubota K, Monden Y, Yagi Y et al. New treatment of the dryeye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol 1999;83: 767-770
  -   Report of the International Dry Eye Work Shop (Dew) April 2007Volume 5, Number 2; 13-14
  -   “A new therapy concept for the treatment of dry eye - theusefulness if phospholipids liposomes” KlimMonatsbl Augenheilkd 2004 oct.221:825-36p